Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Refocused Sophiris to switch to transrectal injection for enlarged prostate drug

This article was originally published in Scrip

Executive Summary

Sophiris Bio will use a transrectal route of administration, rather than the transperineal route, for its lead drug PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate). This follows a three-month 40-patient study which showed that a transrectal ultrasound (TRUS) guided injection directly into the prostate was well tolerated. The selection of the route of administration is another step in a substantial refocusing of the company which saw the appointment of a new CEO, Randall Woods, in mid-August, and a halt to other development projects to allow more resources to be put into the PRX302/BPH program. With its singular focus on the BPH drug, Sophiris hopes to take PRX302 into a Phase III trial later in 2012.

You may also be interested in...



venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

Flagship, ARCH Close VC Funds Totaling $2.56bn

Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.

Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet

Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC018637

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel